Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 2;13(3):811-820.
doi: 10.3390/idr13030073.

Update on the Epidemiology of Macrolide-Resistant Mycoplasma pneumoniae in Europe: A Systematic Review

Daniela Loconsole  1 , Anna Lisa De Robertis  1 , Anna Sallustio  2 , Francesca Centrone  1 , Caterina Morcavallo  1 , Silvia Campanella  1 , Marisa Accogli  1 , Maria Chironna  1
Affiliations
Review

Update on the Epidemiology of Macrolide-Resistant Mycoplasma pneumoniae in Europe: A Systematic Review

Daniela Loconsole et al. Infect Dis Rep. .

Abstract

Macrolide-resistant Mycoplasma pneumoniae (MR-MP) infections cause upper and lower respiratory tract infections in both children and adults, and are characterized by a longer duration of symptoms. Here, we undertook a systematic review of studies on MR-MP in Europe. The review meets PRISMA guidelines. The PubMed, Scopus, and Science Direct databases were searched using suitable keywords to identify relevant studies published from 2010 to 2021; 21 studies were included. Overall, a low level of MR-MP spread was reported in Europe. MR-MP spread increased during epidemic waves registered in Europe, particularly in Italy and Scotland, where the highest MR-MP infection rates were registered during the 2010-2011 epidemic. By contrast, no MR-MP infections were reported in Finland and the Netherlands. Continued monitoring of MR-MP in Europe is needed to maintain the low rates of infection. Moreover, a coordinated and structured pan-European surveillance program adequate for public health surveillance is advisable, with the purpose of containing the spread of antimicrobial resistance.

Keywords: Europe; antimicrobial resistance; epidemiology; macrolide-resistant Mycoplasma pneumoniae; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow chart.
Figure 2
Figure 2
MR-MP prevalence rates reported in the European countries (years 1996–2019).
See this image and copyright information in PMC

References

    1. Jain S., Williams D.J., Arnold S.R., Ampofo K., Bramley A.M., Reed C., Stockmann C., Anderson E.J., Grijalva C.G., Self W.H., et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N. Engl. J. Med. 2015;372:835–845. doi: 10.1056/NEJMoa1405870. - DOI - PMC - PubMed
    1. Shin E.J., Kim Y., Jeong J.Y., Jung Y.M., Lee M.H., Chung E.H. The changes of prevalence and etiology of pediatric pneumonia from National Emergency Department Information System in Korea, between 2007 and 2014. Korean J. Pediatr. 2018;61:291–300. doi: 10.3345/kjp.2017.06100. - DOI - PMC - PubMed
    1. Waites K.B., Talkington D.F. Mycoplasma pneumoniae and its role as a human pathogen. Clin. Microbiol. Rev. 2004;17:697–728. doi: 10.1128/CMR.17.4.697-728.2004. - DOI - PMC - PubMed
    1. Principi N., Esposito S. Macrolide-resistant Mycoplasma pneumoniae: Its role in respiratory infection. J. Antimicrob. Chemother. 2013;68:506–511. doi: 10.1093/jac/dks457. - DOI - PubMed
    1. Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J. Infect. Chemother. 2010;16:162–169. doi: 10.1007/s10156-010-0044-X. - DOI - PubMed

LinkOut - more resources